Nevro

About Nevro

Nevro Corp. is a medical technology company established in 2006 with a mission to alleviate chronic pain through advanced neuromodulation. The company was founded in Menlo Park, California, by Dr. Konstantinos Alataris. Dr. Alataris, an entrepreneur with a Ph.D. in Biomedical Engineering from the University of Southern California, leveraged his background in neuroscience to pioneer a novel approach to spinal cord stimulation. Under his leadership, Nevro developed its core technology and successfully commercialized it internationally. The company achieved significant milestones, including receiving the CE Mark for its Senza system in Europe in 2010 and executing a successful Initial Public Offering (IPO) on the New York Stock Exchange in 2014, which raised approximately $126.5 million.

Nevro's business centers on the design, development, and commercialization of its proprietary platforms for treating chronic pain. Revenue is primarily generated from selling these high-value medical devices through a direct sales force to physicians and hospitals. A critical component of the business model is securing favorable reimbursement from insurance providers and government programs. For the full year 2023, the company reported revenue of $425.17 million. In early 2025, Globus Medical announced it had entered into a definitive agreement to acquire Nevro.

The company's flagship product line is the HFX Spinal Cord Stimulation (SCS) platform, which includes the Senza system, for treating chronic pain in the trunk and limbs, and painful diabetic neuropathy (PDN). The key differentiator of this platform is its proprietary 10 kHz high-frequency therapy, which delivers pain relief without paresthesia—a tingling or buzzing sensation common with traditional low-frequency SCS systems. In 2022, Nevro received FDA approval for its Senza HFX iQ system, which uses artificial intelligence and a patient-facing app to learn from user data and recommend personalized therapy adjustments. This system was developed using data from over 80,000 implanted patients and more than 20 million data points to optimize treatment pathways. Recently, Nevro has expanded its portfolio to include minimally invasive treatments for chronic sacroiliac (SI) joint pain. The Nevro1™ SI Joint Fusion System utilizes a unique transfixing implant with 3D-printed, bone-growth-enhancing technology to provide immediate joint stabilization and promote long-term fusion.